Rapid POC diagnostic for Candida species and multidrug resistance identification

项目总结 侵袭性念珠菌病是由念珠菌引起的一种严重的、公认的真菌感染。抗真菌药 耐药性是念珠菌感染的一个特别问题。耐多药的念珠菌感染很少 剩下的治疗方案。耐药性的类型和水平是未知的，直到引起念珠菌 物种是通过培养方法确定的。一种既能鉴定念珠菌属又能鉴定其菌种的快速诊断试验 抗真菌耐药性将有助于提供及时、适当的治疗，并减少这种疾病的传播。 具有抵抗力的生物。响应CDC为文化独立平台指定的研究主题 针对护理点/低资源环境的念珠菌诊断和耐药性识别技术，Lynntech 建议开发一种快速、廉价、特异和敏感的诊断方法，使看护点假丝酵母菌 无需依赖培养结果即可鉴定出细菌的种类和多重耐药性。我们的创新之处 诊断性检测有效地将高度敏感的分子检测带到了医疗点。Lynntech的诊断 测试可能代表着一种重要的新的医疗诊断范例，以指导准确的治疗 治疗念珠菌感染，并帮助最大限度地提高患者的积极结果。

PROJECT SUMMARY Invasive candidiasis is a serious and widely recognized fungal infection caused by Candida species. Antifungal resistance is a particular problem with Candida infections. Multidrug-resistant Candida infections have very few remaining treatment options. The type and level of drug resistance is unknown until the causative Candida species is determined via culture methods. A rapid diagnostic test to both identify Candida species and its antifungal drug resistance would help provide timely, appropriate treatment and reduce the spread of these resistant organisms. In response to a research topic that is specified by CDC for a culture-independent platform technology for Candida diagnosis and resistance identification for point-of-care/ low-resource settings, Lynntech proposes to develop a rapid, inexpensive, specific, and sensitive diagnostic that enables point-of-care Candida species and multidrug resistance identification without the need to rely on culture results. The innovation of our diagnostic test is effectively bringing highly sensitive molecular testing to point-of-care. Lynntech’s diagnostic test could potentially represent a significant new paradigm in point-of-care diagnosis to guide accurate therapy for Candida infections and help maximize positive patient outcomes.